Clinical trial · Observational
Risk-based Screen and Prognostic Analysis for Second Primary Malignancies in Kidney Cancer Patients
Risk-based Screen and Prognostic Analysis for Second Primary Malignancies in Kidney Cancer Patients: A Retrospective Cohort Study Based on Large-scale Population and Mendelian Randomization Analysis
NCT06531629CI-TRIAL-00079510completedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Second primary malignancy (SPM) significantly impacts the survival and prognosis of patients. This study endeavors to identify risk and prognostic factors associated with SPM after first primary kidney cancer and construct predictive nomograms.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Kidney Cancer | Malignant Kidney Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Surgery, radiation therapy and chemotherapy | Procedure | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- label
- Kidney cancer patients with second primary malignancy (SPM)
- description
- Patients diagnosed with first primary kidney cancer and second primary malignancy between 2000 and 2020
- interventionNames
- Procedure: Surgery, radiation therapy and chemotherapy
- label
- Kidney cancer patients without SPM
- description
- Patients diagnosed with only first primary kidney cancer between 2000 and 2020
- interventionNames
- Procedure: Surgery, radiation therapy and chemotherapy
Primary outcomes (2)
- measure
- Developing a second primary malignancy (SPM)
- timeFrame
- This time was calculated as the time interval from the diagnosis of first primary kidney cancer to the diagnosis of second primary malignancy, assessed up to 20 years.
- description
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 80 Years
Show eligibility criteria text
Inclusion Criteria: * (1) Diagnosed age was between 18 and 80 years old * (2) Diagnosed histologically confirmed as first primary kidney cancer * (3) The staging of kidney cancer was early or localized advanced (T1/2/3N0M0) * (4) Detailed survival data and follow-up information should be provided Exclusion Criteria: * (1) Histological conformation for diagnosis was unavailable * (2) The type of reporting source was "Death certificate only" or "Autopsy only" * (3) Patients with other malignancies before the diagnosis of primary kidney cancer * (4) The staging of kidney cancer was not early or localized advanced (T1/2/3N0M0) * (5) Diagnosis interval between first primary malignancy (FPM) and second primary malignancy (SPM) was less than 6 months * (6) The information was not complete
References
Publications (0)
Data not yet available
No reference posted for this study.